Sprout Pharmaceuticals - About the company
Sprout Pharmaceuticals is an acquired company based in Raleigh (United States), founded in 2011. It operates as a Developer of drugs for hypoactive sexual desire disorder in women. Sprout Pharmaceuticals has raised $185M in funding, with last known valuation of $*****. The company has 31 active competitors, including 11 funded and 6 that have exited. Its top competitors include companies like Gameto, Rejoni and Hope Medicine.
Company Details
Sprout Pharmaceuticals has developed drugs for women's health. The company has developed an FDA-approved non-hormonal pill called ADDYI to cure Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women.
- Phone Number
- +1 **********
- Registered Address
- 4350 Lassiter at North Hills Ave #260 Raleigh, NC 27609
Key Metrics
Founded Year
2011
Location
Raleigh, United States
Stage
Acquired
Total Funding
$185M in 10 rounds
Latest Funding Round
Last Known Valuation
$***** as on Sep 04, 2019
Investors
Ranked
2nd among 31 active competitors
Employee Count
31 as on Feb 28, 2026
Exit Details
Acquired by Bausch Health (Aug 20, 2015)
Legal entities associated with Sprout Pharmaceuticals
Sprout Pharmaceuticals is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Sprout Pharmaceuticals, Inc. CIN: 45-3816411 , United States, Active | Nov 15, 2011 | - | - | - |
Sprout Pharmaceuticals's acquisition details
Sprout Pharmaceuticals got acquired by Bausch Health on Aug 20, 2015 at an acquisition amount of $1B.
Click here to take a look at Sprout Pharmaceuticals's acquisition in detail
Sign up to download Sprout Pharmaceuticals' company profile
Sprout Pharmaceuticals's funding and investors
Sprout Pharmaceuticals has raised a total funding of $185M over 10 rounds. Its first funding round was on Mar 21, 2012. Sprout Pharmaceuticals has 3 institutional investors.
Here is the list of recent funding rounds of Sprout Pharmaceuticals:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Dec 10, 2024 | 6582709 | Series D | 1074155 | 6550029 | 3843665 | 1862962 |
Apr 14, 2023 | 6102186 | Series D | 6692815 | 8688492 | 8437253 | 6573397 |
Aug 15, 2022 | 6579862 | Series D | 4323328 | 6894066 | 5698306 | 9400499 |
View details of Sprout Pharmaceuticals's funding rounds and investors
Sprout Pharmaceuticals' founders and board of directors
Founder? Claim ProfileSprout Pharmaceuticals' employee count trend
Sprout Pharmaceuticals has 31 employees as of Feb 26. Here is Sprout Pharmaceuticals's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Sprout Pharmaceuticals's Competitors and alternates
Top competitors of Sprout Pharmaceuticals include Gameto, Rejoni and Hope Medicine. Here is the list of Top 10 competitors of Sprout Pharmaceuticals, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Gameto 2020, United States, Series C | Developer of therapeutics for the treatment of fertility and menopause | $127M | 58/100 | |
2nd | Sprout Pharmaceuticals 2011, Raleigh (United States), Acquired | Developer of drugs for hypoactive sexual desire disorder in women | $185M | 58/100 | |
3rd | Rejoni 2020, Bedford (United States), Series B | Developer of therapeutics to treat women health conditions | $41.3M | 57/100 | |
4th | Hope Medicine 2018, Shanghai (China), Series B | Developer of monoclonal antibodies for the treatment of multiple diseases | $56M | 56/100 | |
5th | Manufacturer of women care medicines | $19M | 51/100 | ||
6th | ObsEva 2012, Geneva (Switzerland), Public | Developer of therapeutics for women's reproductive health and pregnancy | $94.7M | 47/100 | |
7th | Forendo Pharma 2013, Turku (Finland), Acquired | Provider of small molecule based therapeutics for reproductive health | $25.6M | 46/100 | |
8th | PregLem 2006, Geneva (Switzerland), Acquired | Drugs for women's reproductive medicine | $57.9M | 45/100 | |
9th | FimmCyte 2022, Basel (Switzerland), Funding Raised | Developer of therapeutics to treat endometriosis | - | 44/100 | |
10th | Nora Therapeutics 2007, Palo Alto (United States), Series B | Developer of therapeutics to address IVF failure and recurrent pregnancy loss | $37.8M | 43/100 |
Looking for more details on Sprout Pharmaceuticals's competitors? Click here to see the top ones
Sprout Pharmaceuticals's Investments and acquisitions
Sprout Pharmaceuticals has made no investments or acquisitions yet.
Reports related to Sprout Pharmaceuticals
Here is the latest report on Sprout Pharmaceuticals's sector:
News related to Sprout Pharmaceuticals
Media has covered Sprout Pharmaceuticals for a total of 3 events in the last 1 year, 1 of them has been about company updates.
•
Sprout Pharmaceuticals' Addyi® named "Best Prescription for Low Libido"PR Newswire•Jan 29, 2026•Sprout Pharmaceuticals
•
•
Med-Spas Expand Beyond Aesthetics with Addyi for Better SexIndie Beauty Media Group LLC•Jul 25, 2025•ADDYI, Sprout Pharmaceuticals
•
•
Sprout Pharma adds $2.9M to funding round, now nearly $28MWRAL TechWire•Aug 17, 2022•Sprout Pharmaceuticals
•
Raleigh’s Sprout Pharma’s funding round surpasses $25M raised with 85 investors so farWRAL TechWire•May 06, 2022•Sprout Pharmaceuticals
•
•
•
•
Are you a Founder ?
FAQs about Sprout Pharmaceuticals
Explore our recently published companies
- Wizzme - Bengaluru based, 2025 founded, Unfunded company
- Astrovirgo.ai - Unfunded company
- Seed Lab - United Kingdom based, 2026 founded, Unfunded company